Investment Thesis
Endonovo Therapeutics is in severe financial distress with negative stockholders' equity of -$23.0M, indicating the company is technically insolvent. Despite reporting a $8.5M net income anomaly, the company is burning cash at -$407K in free cash flow, has zero liquidity, and minimal revenue of $134.3K cannot support $7.1M in long-term debt and $23.8M in total liabilities.
Strengths
- Exceptional gross margin of 96.4% indicates strong pricing power on products sold
- Revenue growth of 110.2% YoY shows market demand for offerings
- Minimal capital expenditure needs suggest asset-light business model
Risks
- Negative stockholders' equity of -$23.0M represents technical insolvency and existential solvency risk
- Zero cash and equivalents with negative operating cash flow of -$404.4K indicates immediate liquidity crisis
- Revenue of $134.3K cannot service $7.1M long-term debt and $23.8M total liabilities; unsustainable capital structure
- Current ratio and quick ratio of 0.00x confirm complete inability to meet short-term obligations
- Anomalous $8.5M net income amid operational losses suggests one-time gains or accounting adjustments masking underlying distress
Key Metrics to Watch
- Operating cash flow trend - must turn positive to indicate business viability
- Cash position and liquidity - any additional capital raise or debt restructuring
- Revenue growth sustainability - whether 110% growth can accelerate to meaningful absolute levels ($1M+)
- Stockholders' equity path to positive - requires sustained profitability or capital injection
Financial Metrics
Revenue
134.3K
Net Income
8.5M
EPS (Diluted)
$0.00
Free Cash Flow
-407.0K
Total Assets
815.8K
Cash
0.0
Profitability Ratios
Gross Margin
96.4%
Operating Margin
-1,589.0%
Net Margin
6,351.8%
ROE
N/A
ROA
1,045.4%
FCF Margin
-303.1%
Balance Sheet & Liquidity
Current Ratio
0.00x
Quick Ratio
0.00x
Debt/Equity
N/A
Debt/Assets
2,914.6%
Interest Coverage
-2.27x
Long-term Debt
7.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-24T08:06:11.765332 |
Data as of: 2023-09-30 |
Powered by Claude AI